Product
paclitaxel
Aliases
Taxol, TAXOL®
28 clinical trials
35 indications
Indication
Anal Canal Squamous Cell CarcinomaIndication
Breast Cancer (HER2-positive)Indication
HER2-positive Gastric CancerIndication
HER2-positive solid tumorsIndication
ERBB2 AmplificationIndication
Colorectal CancerIndication
Breast CancerIndication
CancerIndication
Advanced Non-small-cell Lung CancerIndication
Lung CancerIndication
Ovarian CancerIndication
Esophageal squamous cell carcinomaIndication
Breast NeoplasmsIndication
Fallopian Tube NeoplasmsIndication
Primary Peritoneal NeoplasmIndication
Stomach AdenocarcinomaIndication
Esophageal CancerIndication
Esophageal adenocarcinomaIndication
lung cancerIndication
BreastIndication
PersistentIndication
RecurrentIndication
Cervical CancerIndication
Esophageal cancerIndication
Esophagogastric Junction CarcinomaIndication
Head and Neck Squamous CarcinomaIndication
Stomach CancerIndication
Renal Cell CarcinomaIndication
Bladder CancerIndication
Gastric AdenocarcinomaIndication
Small Cell Lung CarcinomaIndication
Endometrial NeoplasmsIndication
NSCLCClinical trial
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)Status: Active (not recruiting), Estimated PCD: 2024-10-24
Clinical trial
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast CancerStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2014-09-30
Clinical trial
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-09-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)Status: Active (not recruiting), Estimated PCD: 2021-08-09
Clinical trial
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2011-10-10
Clinical trial
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based ChemotherapyStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)Status: Active (not recruiting), Estimated PCD: 2028-07-21
Clinical trial
A Randomized, Double-blind, Phase 3 Study Of Cadonilimab (AK104) Plus Pulocimab (AK109) And Paclitaxel Versus Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma Who Failed First-line ImmunochemotherapyStatus: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian CancerStatus: Terminated, Estimated PCD: 2012-11-01
Clinical trial
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)Status: Completed, Estimated PCD: 2018-09-04
Clinical trial
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III TrialStatus: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2009-07-31
Clinical trial
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)Status: Completed, Estimated PCD: 2018-09-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)Status: Completed, Estimated PCD: 2019-02-20
Clinical trial
Drug Treatment Patterns and Effects for Metastatic Non-small Cell Lung Cancer Patients In NORway (DELINOR)Status: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)Status: Completed, Estimated PCD: 2018-10-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)Status: Active (not recruiting), Estimated PCD: 2025-05-31
Clinical trial
A Prospective, Randomized, Open-label, Phase III Trial of Chemotherapy With Carboplatin And Paclitaxel, Versus Carboplatin And Paclitaxel In Combination With ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha In Patients With Advanced, Previously Untreated Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2002-09-09
Clinical trial
A Multicenter, Open Phase Ib Study to Evaluate the Efficacy and Safety of SCT-I10A in Combination With SCT200 or SCT200 in Combination With Paclitaxel/Docetaxel in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary TumorsStatus: Completed, Estimated PCD: 2021-08-20
Clinical trial
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line TherapyStatus: Completed, Estimated PCD: 2012-05-11
Clinical trial
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)Status: Active (not recruiting), Estimated PCD: 2026-07-17
Clinical trial
A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian CancerStatus: Completed, Estimated PCD: 2016-08-08